Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bionano Genomics Inc (NQ: BNGO )

0.2240 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bionano Genomics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Is Bionano Genomics (BNGO) Stock Up 20% Today?
Bionano Genomics is in the news again, delivering groundbreaking nanoscale analytics research that has BNGO stock reaching for the stars. 
Via InvestorPlace
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Thursday, 7/28, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
The 7 Best Stocks to Buy on a Dip in July
With the stock market pricing in a recession that likely won't arrive anytime soon, these are some of the best stocks to buy on a dip. 
Via InvestorPlace
3 Stocks That Could Double in 2022
With the market shaking off its downturn and the economy strengthening, there are several stocks that could double before the year is out. 
Via InvestorPlace
Looking Into Bionano Genomics's Return On Capital Employed
Bionano Genomics (NASDAQ:BNGO) brought in sales totaling $5.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 30.52%, resulting in a loss of $29.95 million. 
Via Benzinga
Hold On to Bionano Genomics Stock Until It Reaches $6 at Least
After a year of blockbuster revenue growth, BNGO stock deserves a major re-rating 
Via InvestorPlace
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS. 
Via Benzinga
Recap: Bionano Genomics Q2 Earnings
Bionano Genomics (NASDAQ:BNGO) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Bionano Genomic (BNGO) Stock Pops on Research Study
Bionano Genomic is in the news today as a landmark research focusing on genomic mapping technology bolsters BNGO stock. 
Via InvestorPlace
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
Bionano Genomics's Earnings Outlook
Bionano Genomics (NASDAQ:BNGO) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Bionano... 
Via Benzinga
The Latest Studies by Bionano Genomics Are Promising, But It’s Not a Buy Yet
BNGO stock has provided positive news from study results lately, but its fundamentals are not great and not a reason to invest in it now. 
Via InvestorPlace
Why Bionano Genomics Stock Is Risky, but a Good Bet
The risks may be clear when it comes to Bionano Genomics and BNGO stock. However, investors should see this as a long-term play. 
Via InvestorPlace
Bionano Genomics Stock Can Regain the Crucial $5 Level
Bionano Genomics is working hard to address rare diseases, yet Wall Street doesn't see the value in BNGO stock -- but that could change soon. 
Via InvestorPlace
Bionano Genomics May Finally Offer a Reward for Your Risk
BNGO stock has been a falling knife for the past year. But, with promising fundamentals and good tailwinds, now be the time to take a chance. 
Via InvestorPlace
Bionano Genomics's Return On Capital Employed Insights
Benzinga Pro data, Bionano Genomics (NASDAQ:BNGO) reported Q4 sales of $6.30 million. Earnings fell to a loss of $22.95 million, resulting in a 10.58% decrease from last quarter... 
Via Benzinga
Bionano Genomics's Earnings Outlook
Bionano Genomics (NASDAQ:BNGO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Bionano Genomics Has Attractive Applications But An Unattractive Stock Price
BNGO stock will witness more hard times until profitability is improved and sales start to rebound. That could take some time. 
Via InvestorPlace
Bionano Stock Looks to Have a Monster Comeback in Its Future
Bionano's Saphyr appears to be able to help doctors treat leukemia, and the adoption of its device is growing rapidly. 
Via InvestorPlace
Investors Have Cast Their ‘No’ Votes Against Bionano Genomics
A preliminary report from Bionano Genomics doesn't tell the full story and a lack of profitability will likely weigh on BNGO stock. 
Via InvestorPlace
Bionano Is Not the Genomics Stock To Bet On
Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now. 
Via InvestorPlace
Bionano Genomics Is Interesting as Genome Testing Scales Upwards
BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing. 
Via InvestorPlace
Bionano Genomics Preliminary Q4, FY21 Revenue Exceed Expectations
Bionano Genomics Inc (NASDAQ: BNGO) posted preliminary Q4 sales of $5.8 million - $6.2 million, +25% - 33% sequentially, up 45% - 55% Y/Y, and above the consensus... 
Via Benzinga
7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now
These cheap stocks under $10 are poised to rally in the new, more friendly macro environment that's in place as 2022 unfolds. 
Via InvestorPlace
Bionano Genomics Stock Is a Low-Priced Bet on Sound Science
Even though BNGO stock investors struggled in 2021, prepare for new price discovery as Bionano pushes the envelope in optical genome mapping. 
Via InvestorPlace
The Critics Are Wrong About Bionano Stock
The critics of Bionano are greatly underestimating the vast potential of Saphyr and of BNGO stock for long-term investors. 
Via InvestorPlace
This Analyst’s Saphyr Calculations Suggest Buying Bionano While It’s Down
If BNGO stock reaches Oppenheimer’s price target, investors are looking at a return of more than 300%, plus long-term growth potential. 
Via InvestorPlace
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ... 
Via Benzinga
Bionano Genomics Proves Not Everything Genetic is Gold
Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.